Soleno Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, with a particular focus on Prader-Willi syndrome. In March 2025, the company secured FDA approval for its first and only treatment targeting hyperphagia in PWS, marking a significant milestone in addressing a critical unmet medical need. Leveraging a rigorous scientific approach alongside strong advocacy and community engagement, Soleno blends cutting-edge research with patient-centric values to deliver impactful solutions. The organization fosters a collaborative culture that empowers scientists, clinicians, and patients to work together toward transformative health outcomes.
The Director/Senior Director, GVP Quality Assurance, is responsible for supporting the development, coordination and implementation of Global Pharmacovigilance regulations related to quality assurance activities. This individual will serve as the primary QA inspection lead for pharmacovigilance activities, ensuring that Soleno maintains continuous inspection readiness across PV systems, vendors, and processes/documents at all times.
Soleno Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, with a particular focus on Prader-Willi syndrome. In March 2025, the company secured FDA approval for its first and only treatment targeting hyperphagia in PWS, marking a significant milestone in addressing a critical unmet medical need. Leveraging a rigorous scientific approach alongside strong advocacy and community engagement, Soleno blends cutting-edge research with patient-centric values to deliver impactful solutions. The organization fosters a collaborative culture that empowers scientists, clinicians, and patients to work together toward transformative health outcomes.
Padagis LLC